SCYNEXIS Presents New In Vivo Data Highlighting the Potential of SCY-078 Used in Combination for the Treatment of Aspergillus Infections at AAA 2018
The oral presentation, titled "Combination Therapy with SCY-078 and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis," delivered by the infectious diseases translational research team from Weill Cornell Medicine of
- Date and Time:
Thursday, February 1from 14.55-15.10 WET
- Session: Therapy for the Next Decade
"The data presented at AAA show synergistic activity of SCY-078 at two different doses in combination with ISA against Aspergillus in a relevant in vivo model, suggesting the potential for improved patient outcomes for this high-mortality infection with significant unmet medical need," said
In the in vivo study, conducted using an established model of experimental IPA, neutropenic rabbits were divided into four experimental study groups where treatment involved either a daily IV administration of a low (2.5mg/kg/day) or high dose (7.5mg/kg/day) of SCY-078; a single dose (40mg/kg/day) of ISA; a combination of either the low or high dose of SCY-078 with ISA; or no treatment as part of the untreated control group. The following results were observed:
- Prolonged survival in rabbits treated with both combination groups compared to all single-therapy arms (p<0.05);
- Decreased infarct scores in rabbits treated with both combination groups compared to all single-therapy arms (p<0.01); and
- Lower serum GMI in rabbits treated with combination regimen of SCY7.5+ISA40 compared to the single therapy arms of SCY7.5, ISA40, and untreated controls (p<0.05).
These results further confirm in vitro data that demonstrated the synergistic and additive activity of SCY-078 in combination with ISA against Aspergillus spp.
The presentation is available on the
SCY-078 is an investigational antifungal agent that is a semi-synthetic derivative of the natural product enfumafungin. SCY-078 is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. This agent combines the well-established activity of glucan synthase inhibitors with the potential flexibility of having IV and oral formulations. SCY-078 is currently in development for the treatment of fungal infections caused primarily by Candida (including C. auris) and Aspergillus species. It has demonstrated broad spectrum of anti-fungal activity, in vitro and in vivo, against multi-drug resistant pathogens, including azole- and echinocandin-resistant strains. The FDA granted Fast Track, Qualified Infectious Disease Product and Orphan Drug Designations for the formulations of SCY-078 for the indications of invasive candidiasis (including candidemia) and invasive aspergillosis.
Forward Looking Statement
Statements contained in this press release maybe, "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited, to: risks inherent in
MacDougall Biomedical Communications
View original content:http://www.prnewswire.com/news-releases/scynexis-presents-new-in-vivo-data-highlighting-the-potential-of-scy-078-used-in-combination-for-the-treatment-of-aspergillus-infections-at-aaa-2018-300591610.html